TY - JOUR
T1 - TGF-β1 signaling and Krüppel-like factor 10 regulate bone marrow-derived proangiogenic cell differentiation, function, and neovascularization
AU - Wara, Akm Khyrul
AU - Foo, Shi Yin
AU - Croce, Kevin
AU - Sun, Xinghui
AU - Icli, Basak
AU - Tesmenitsky, Yevgenia
AU - Esen, Fehim
AU - Lee, Jung Soo
AU - Subramaniam, Malayannan
AU - Spelsberg, Thomas C.
AU - Lev, Eli I.
AU - Leshem-Lev, Dorit
AU - Pande, Reena L.
AU - Creager, Mark A.
AU - Rosenzweig, Anthony
AU - Feinberg, Mark W.
PY - 2011/12/8
Y1 - 2011/12/8
N2 - Emerging evidence demonstrates that proangiogenic cells (PACs) originate from the BM and are capable of being recruited to sites of ischemic injury where they contribute to neovascularization. We previously determined that among hematopoietic progenitor stem cells, common myeloid progenitors (CMPs) and granulocyte-macrophage progenitor cells (GMPs) differentiate into PACs and possess robust angiogenic activity under ischemic conditions. Herein, we report that a TGF-β1-responsive Krüppel-like factor, KLF10, is strongly expressed in PACs derived from CMPs and GMPs, ∼60-fold higher than in progenitors lacking PAC markers. KLF10-/- mice present with marked defects in PAC differentiation, function, TGF-β responsiveness, and impaired blood flow recovery after hindlimb ischemia, an effect rescued by wild-type PACs, but not KLF10-/- PACs. Overexpression studies revealed that KLF10 could rescue PAC formation from TGF-β1-/- CMPs and GMPs. Mechanistically, KLF10 targets the VEGFR2 promoter in PACs which may underlie the observed effects. These findings may be clinically relevant because KLF10 expression was also found to be significantly reduced in PACs from patients with peripheral artery disease. Collectively, these observations identify TGF-β1 signaling and KLF10 as key regulators of functional PACs derived from CMPs and GMPs and may provide a therapeutic target during cardiovascular ischemic states.
AB - Emerging evidence demonstrates that proangiogenic cells (PACs) originate from the BM and are capable of being recruited to sites of ischemic injury where they contribute to neovascularization. We previously determined that among hematopoietic progenitor stem cells, common myeloid progenitors (CMPs) and granulocyte-macrophage progenitor cells (GMPs) differentiate into PACs and possess robust angiogenic activity under ischemic conditions. Herein, we report that a TGF-β1-responsive Krüppel-like factor, KLF10, is strongly expressed in PACs derived from CMPs and GMPs, ∼60-fold higher than in progenitors lacking PAC markers. KLF10-/- mice present with marked defects in PAC differentiation, function, TGF-β responsiveness, and impaired blood flow recovery after hindlimb ischemia, an effect rescued by wild-type PACs, but not KLF10-/- PACs. Overexpression studies revealed that KLF10 could rescue PAC formation from TGF-β1-/- CMPs and GMPs. Mechanistically, KLF10 targets the VEGFR2 promoter in PACs which may underlie the observed effects. These findings may be clinically relevant because KLF10 expression was also found to be significantly reduced in PACs from patients with peripheral artery disease. Collectively, these observations identify TGF-β1 signaling and KLF10 as key regulators of functional PACs derived from CMPs and GMPs and may provide a therapeutic target during cardiovascular ischemic states.
UR - http://www.scopus.com/inward/record.url?scp=83455219317&partnerID=8YFLogxK
U2 - 10.1182/blood-2011-06-363713
DO - 10.1182/blood-2011-06-363713
M3 - Article
C2 - 21828131
AN - SCOPUS:83455219317
SN - 0006-4971
VL - 118
SP - 6450
EP - 6460
JO - Blood
JF - Blood
IS - 24
ER -